Immunotherapy in non-metastatic urothelial cancer: back to the ‘future’

References

• Cancer Today (n.d.). [cited 2019 Apr 11]. Available from: http://gco/iarc/fr/today/online-analysis-multi-bars?
   Google Scholar
• Rouanne M, Roumiguié M, Houédé N, et al. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol. 2018;36(11):1727–1740.
   PubMed Web of Science ®Google Scholar
• FDA. Press release. [cited 2016 May 18]. Available from: https://www.fda.gov
   Google Scholar
• FDA. Press release. [cited 2017 May 08]. Available from: https://www.fda.gov
   Google Scholar
• FDA. Press release. [cited 2017 Feb 02]. Available from: https://www.fda.gov
   Google Scholar
• FDA. Press release. [cited 2017 May 09]. Available from: https://www.fda.gov
   Google Scholar
• FDA. Press release. [cited 2017 May 01]. Available from: https://www.fda.gov
   Google Scholar
• Scosyrev E, Noyes K, Feng C, et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2008;115(1):68–74.
   Web of Science ®Google Scholar
• Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4.
   PubMed Web of Science ®Google Scholar
• Fuge O, Vasdev N, Allchorne P, et al. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79.
   PubMed Web of Science ®Google Scholar
• Smaldone MC, Jacobs BL, Smaldone AM, et al. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology. 2008;72(3):613–616.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Isbarn H, Shariat SF, et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009;74(4):858–864.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Powles T, Vogelzang N. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67.
   PubMed Web of Science ®Google Scholar
• Guo H, Tsung K. Tumor reductive therapies and antitumor immunity. Oncotarget. 2017 Jun 14;8(33):55736–55749.
   PubMedGoogle Scholar
• Approved drugs > FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. n.d.. [cited 2019 Mar 12]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm597248.htm
   Google Scholar
• Solsona E. Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2014;65(4):847–848.
   PubMed Web of Science ®Google Scholar
• Liu D, Plimack E, Hoffman-Censits J, et al. Clinical validation of chemotherapy response biomarkerERCC2in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2016;2(8):1094.
   PubMed Web of Science ®Google Scholar
• Groenendijk F, de Jong J, Fransen van de Putte E, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69(3):384–388.
   PubMed Web of Science ®Google Scholar
• Vashistha V, Wang H, Mazzone A, et al. Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–1020.
   PubMed Web of Science ®Google Scholar
• Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the memorial sloan-kettering cancer center experience and recommendations for patient selection. J Urol. 2004;172(3):878–881.
   PubMed Web of Science ®Google Scholar
• Kassouf W, Swanson D, Kamat AM, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006;175(6):2058–2062.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Isbarn H, Shariat SF, et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009;74:858.
   PubMed Web of Science ®Google Scholar
• Mitra AP, Alemozaffar M, Harris BN, et al. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Urology. 2014;84:1420.
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Jackson AM, O’Donnell MA, et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165):1689–1694.
   PubMed Web of Science ®Google Scholar
• De Boer EC, De Jong WH, Steerenberg PA, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus C-Guérin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34(5):306–312.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Briggman J, Urbauer DL, et al. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guérin. Eur Urol. 2016;69(2):197–200.
   PubMed Web of Science ®Google Scholar
• Brandau S, Riemensberger J, Jacobsen M, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer. 2001;92(5):697–702.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Brausi MA, Kirkels WJ, et al., EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–773. .
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. World J Urol. 2009;27(3):319–324.
   PubMed Web of Science ®Google Scholar
• Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011;29(3):259–264.
   PubMed Web of Science ®Google Scholar
• Keynote 57: a phase II clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in subjects with high risk Non-muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy. Bladder Cancer. n.d. [cited 2019 Mar 12]. Available from: http://www.bladdercancerjournal.com/keynote-57-phase-ii-clinical-trial-study-efficacy-and-safety-pembrolizumab-mk-3475-subjects-high
   Google Scholar
• Assessment of efficacy and safety of durvalumab plus BCG compared to the standard therapy with BCG in non-muscle invasive bladder cancer (POTOMAC) NCT03528694
   Google Scholar
• A study of nivolumab or nivolumab plus experimental medication BMS-986205 with or without Bacillus Calumette-Guerin (BCG) in BCG unresponsive bladder cancer that has not invaded into the muscle wall of the bladder (checkmate 9UT) NCT03519256
   Google Scholar
• Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68(6):959–967.
   PubMed Web of Science ®Google Scholar
• Iyer G, Balar AV, Milowsky MI, et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol. 2018;36(19):1949–1956.
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Abbosh P, Zibelman MR, et al. A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC. J Clin Oncol. 2018;36(6_suppl):TPS537–TPS537.
   Web of Science ®Google Scholar
• Tan TZ, Rouanne M, Tan KT, et al. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol. 2019;75(3):423–432.
   PubMed Web of Science ®Google Scholar
• Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544–554.
   PubMed Web of Science ®Google Scholar
• Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353–3360.
   PubMed Web of Science ®Google Scholar
• A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS). OncologyPRO. n.d. [cited 2019 Mar 12]. Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/A-phase-II-study-investigating-the-safety-and-efficacy-of-neoadjuvent-atezolizumab-in-muscle-invasive-bladder-cancer-ABACUS
   Google Scholar
• Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895–1901.
   PubMed Web of Science ®Google Scholar
• A phase Ib/2 study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced Urothelial Cancer (UC). OncologyPRO. n.d. [cited 2019 Feb 10]. Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/A-Phase-Ib-2-study-of-neoadjuvant-pembrolizumab-pembro-and-chemotherapy-for-locally-advanced-Urothelial-Cancer-UC
   Google Scholar
• Chism D, Woods M, Milowsky M. Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. Oncologist. 2013;18(8):933–940.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Goldman B, Speights V, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–4109.
   PubMed Web of Science ®Google Scholar
• Bhindi B, Frank I, Mason R, et al. Survival for patients with residual tumor at radical cystectomy following chemotherapy: a matched analysis to cystectomy-only patients. J Clin Oncol. 2017;35(6_suppl):355.
   Web of Science ®Google Scholar
• Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018;9:185.
   PubMed Web of Science ®Google Scholar
• Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54.
   PubMed Web of Science ®Google Scholar
• Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J clin oncol. n.d. [cited 2019 Mar 14]. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.18_suppl.lba4518
   Google Scholar
• Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012;23(3):695–700.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76–86.
   PubMed Web of Science ®Google Scholar
• Seisen T, Jamzadeh A, Leow JJ, et al. Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. JAMA Oncol. 2018;4(2):225–229.
   PubMed Web of Science ®Google Scholar
• Phase III Randomised Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation (n.d.). [cited 2019 Apr 11]. Available from: https://www.urology.com/clinical-trials/blaadder-cancer/99107
   Google Scholar
• IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients with muscle-invasive urothelial carcinoma. Cochrane Library (n.d.). [cited 2019 Apr 11]. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01418105/full
   Google Scholar
• A Phase III Randomised Double-blind Multi-center Study of Adjuvant Nivolumab vs Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274). [cited 2019 Apr 11]. Available from: http:/www/urotoday.com/clinical-trials/bladder-carcinoma/95806
   Google Scholar
• Birtle AJ, Chester JD, Jones RJ, et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol. 2018. DOI:10.1200/JCO.2018.36.6_suppl.407
   Google Scholar